SCHEMBL4839072

SCHEMBL4839072

c1ccc2nc(N3C[C@@H]4C[C@H]3CN4)ccc2c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
CSNK1E P49674 1/20 0.49
IRAK4 Q9NWZ3 1/20 0.48
CHRNB2 P17787 3/20 0.47
CHRNA4 P43681 3/20 0.47
CHRNB4 P30926 1/20 0.47
CHRNA3 P32297 1/20 0.47
PARP1 P09874 1/20 0.47
MCHR1 Q99705 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4848007 0.78 ALDH1A1 (0.53) CHRNB2CHRNA4MCHR1
SCHEMBL15217040 0.74 CHRNB2 (0.49) CHRNB2CHRNA4CHRNB4CHRNA3PARP1
SCHEMBL2227813 0.74 CHRNB2 (0.54) CHRNB2CHRNA4CHRNB4CHRNA3
SCHEMBL23060637 0.74 CHRNB2 (0.54) CHRNB2CHRNA4CHRNB4CHRNA3
SCHEMBL2227430 0.74 CHRNB2 (0.54) CHRNB2CHRNA4CHRNB4CHRNA3
SCHEMBL7094041 0.73 CHRNA7 (0.56) PARP1
SCHEMBL4839016 0.73 CHRNA7 (0.56) PARP1
SCHEMBL19281800 0.73 CYP1A2 (0.40) IRAK4
SCHEMBL5041622 0.73 CHRNB2 (0.60) CHRNB2CHRNA4CHRNB4CHRNA3
SCHEMBL5370480 0.73 CHRNB2 (0.60) CHRNB2CHRNA4CHRNB4CHRNA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7329754-B2 2,5-diazabicyclo[2.2.1]heptane derivatives NEUROSEARCH A/S (DK) 2008-02-12 US claimed
EP-1368348-B1 NOVEL 2,5-DIAZABICYCLO(2.2.1)HEPTANE DERIVATIVES NEUROSEARCH AS (DK) 2005-01-19 EP claimed
US-20040181069-A1 Novel 2,5-diazabicyclo[2.2.1]heptane derivatives DANPET AB (SE) 2004-09-16 US claimed
EP-1368348-A1 NOVEL 2,5-DIAZABICYCLO(2.2.1)HEPTANE DERIVATIVES NEUROSEARCH A/S (DK) 2003-12-10 EP claimed
WO-2002070522-A1 NOVEL 2,5-DIAZABICYCLO[2.2.1]HEPTANE DERIVATIVES NEUROSEARCH A/S (DK) 2002-09-12 WO claimed
US-7329754-B2 2,5-diazabicyclo[2.2.1]heptane derivatives NEUROSEARCH A/S (DK) 2008-02-12 US disclosed
EP-1368348-B1 NOVEL 2,5-DIAZABICYCLO(2.2.1)HEPTANE DERIVATIVES NEUROSEARCH AS (DK) 2005-01-19 EP disclosed
US-20040181069-A1 Novel 2,5-diazabicyclo[2.2.1]heptane derivatives DANPET AB (SE) 2004-09-16 US disclosed
EP-1368348-A1 NOVEL 2,5-DIAZABICYCLO(2.2.1)HEPTANE DERIVATIVES NEUROSEARCH A/S (DK) 2003-12-10 EP disclosed
WO-2002070522-A1 NOVEL 2,5-DIAZABICYCLO[2.2.1]HEPTANE DERIVATIVES NEUROSEARCH A/S (DK) 2002-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040181069-A1 Novel 2,5-diazabicyclo[2.2.1]heptane derivatives CHRNA2, CHRNB2, CHRNA10 CSNK1E 2734/4885IRAK4 1768/4885CHRNB2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.